ArticleMolecular neurobiology2025
LINC00265 Serves as a Diagnostic and Prognostic Marker for Acute Ischemic Stroke and INHIBITS Disease Progression Through the miR- 155 - 5p/TRIM32 Axis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- LncRNA HOTAIR/miR-9-5p/FOXP1 axis modulates cerebral ischemia-reperfusion injury via NLRP3 inflammasome activation.IBRO neuroscience reports · 2026Article
- Serum miR-369-3p Downregulation Correlates with Poor Prognosis in Acute Ischemic Stroke and Mitigates Endothelial Injury by Targeting VAV3.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke (AIS) is a medical emergency stemming from a reduction in cerebral blood supply, leading to neuronal injury. LINC00265 may emerge as a highly promising biomarker for stroke. The aim of this investigation was to investigate the clinical and prognostic significance of LINC00265 in AIS, as well as to elucidate the molecular mechanisms through which LINC00265 influences AIS. Blood samples were collected from 131 AIS patients. qRT-PCR was employed to measure the expression levels of LINC00265. The diagnostic and prognostic value of LINC00265 were evaluated using ROC curve and Kaplan-Meier survival curves, respectively. To establish an in vitro model of AIS, HCMIEC/D3 cells were subjected to OGD/R treatment. Cell proliferation was assessed using CCK-8 assay. The concentrations of TNF-α, IL-6, IL-1β, IL-4, and IL-10 were measured using ELISA kit. The protein expression levels of VCAM-1 and ICAM-1 were detected by Western blot analysis. The expression of LINC00265 was found to be significantly downregulated in AIS patients and strongly correlated with disease severity. The reduced expression of LINC00265 exhibited considerable significance for both diagnosis and prognosis prediction of AIS. At the mechanistic level, LINC00265 mitigated OGD/R-induced cellular injury by modulating the miR-155-5p/TRIM32 axis. Therefore, overexpression of LINC00265 may potentially suppress disease progression in AIS by regulating miR-155-5p/TRIM32 axis.
Indexed as
Identifiers
40317416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.